导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.08% | 2501/4773 |
| 近一周 | -2.99% | 3519/5462 |
| 近一月 | -7.67% | 3921/5421 |
| 近一季 | -14.00% | 4113/5209 |
| 近半年 | -2.76% | 2009/4920 |
| 近一年 | 1.25% | 2374/4366 |
| 近两年 | 57.75% | 1271/2954 |
| 近三年 | 29.65% | 1068/2253 |
| 成立以来 | 72.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.61% 2385/4961 |
20.63% 1215/5312 |
- - |
- - |
| 2025 | 25.91% 1669/4813 |
-0.73% 2381/3635 |
-0.57% 2967/4076 |
30.05% 1199/4524 |
-1.91% 3035/4813 |
| 2024 | 12.61% 1229/3463 |
0.32% 998/2808 |
-3.36% 1356/3014 |
19.85% 801/3129 |
-3.08% 2255/3463 |
| 2023 | -15.53% 1653/2656 |
4.32% 985/2280 |
-6.12% 1591/2385 |
-7.35% 1560/2515 |
-6.90% 1971/2655 |
| 2022 | -24.27% 1204/2207 |
-18.17% 1308/1919 |
8.93% 316/2016 |
-16.39% 1450/2113 |
1.63% 1196/2208 |
| 2021 | 0.12% 728/1822 |
-4.55% 872/1255 |
10.34% 473/1330 |
-7.65% 1070/1466 |
2.93% 494/1822 |
| 2020 | 48.19% 188/1250 |
-5.45% 419/1028 |
21.24% 238/1067 |
10.16% 579/1164 |
17.35% 130/1184 |
| 2019 | 53.47% 82/1092 |
36.33% 87/754 |
-3.10% 375/804 |
4.86% 177/850 |
10.79% 96/918 |
| 2018 | -32.06% 517/834 |
- - |
- - |
- - |
-13.82% 560/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达深证100ETF联接C VS. 长安沪深300非周期A(740101) |